Wire Stories
850A Mysterious Big Win Adventure Awaits at Ozwin
New online casino takes Australian players on a thrilling journey where mystery bonuses and big wins await SYDNEY–(BUSINESS WIRE)–Ozwin is a brand-new...
- 810
Global & Chinese Sodium Sulfite Market Insights 2020 – Analysis & Forecast – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Sodium Sulfite Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application” report...
- 734
Global & Chinese Safety & Easy-Open Plastic Closure Market Insights 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Safety & Easy-Open Plastic Closure Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions,...
- 755
Global and Chinese Glucose Oxidase Market Insights 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glucose Oxidase Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application” report...
- 776
China Approves AUSTEDO® For Treating Chorea Associated with Huntington’s Disease and Tardive Dyskinesia in Adults
TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has...
- 849
Global & Chinese Market Sodium Thiocyanate Market Insights 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Sodium Thiocyanate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application” report...
- 939
Sea Limited Reports First Quarter 2020 Results
SINGAPORE–(BUSINESS WIRE)–Sea Limited (NYSE: SE) (“Sea” or the “Company”) today announced its financial results for the first quarter ended March 31, 2020....
- 750
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
In a Phase 3 study, SB11 demonstrated equivalent efficacy in terms of change in best corrected visual activity (BCVA) at Week 8...
- 1.0K
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Designation based on phase 2 DESTINY-Lung01 This is the third Breakthrough Therapy Designation for ENHERTU, highlighting its potential to treat multiple HER2...
- 825
Accenture Acquires Byte Prophecy to Enhance AI and Digital Analytics Capabilities in Emerging Markets
Acquisition to improve speed and agility of delivering advanced analytics, data and AI solutions to enterprises AHMEDABAD, India–(BUSINESS WIRE)–Accenture (NYSE: ACN) has...
